

Medtronic plc Q2 FY24

Earnings presentation

November 21, 2023

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this presentation, including to reflect future events or circumstances.

Non-GAAP financial measures

Certain information in this presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material. This presentation contains financial measures and guidance which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. All GAAP to non-GAAP reconciliations are provided on our website.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as non-GAAP adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

Financial comparisons

References to results increasing, decreasing, or remaining flat are in comparison to the same period in the prior fiscal year. References to organic revenue growth exclude the impact of significant acquisitions or divestitures and currency. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to sequential revenue changes are made on an "as reported" basis. Unless stated otherwise, all references to share gains or losses are as of the most recently completed calendar quarter, on a revenue basis, and in comparison to the same period in the prior year.

Table ofExecutivePortfolioFinancialGuidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

Table of contents





Table of
ContentsExecutive
PortfolioPortfolio
FinancialGuidance &
Guidance &
SustainabilitySustainabilityAppendix

O2 FY24 Executive Summary

Q2 FY24 Key messages

Table of Executive Portfolio Financial Guidance & Sustainability Appendix Contents Summary Highlights Highlights Assumptions

Solid execution results in MSD revenue growth driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raising FY24 guidance



A Broad-based performance across businesses and major geographies

Sustained end-market health, innovative product launches and commercial focus drove Q2 results; broad strength - Cardiovascular, Neuroscience & Medical Surgical all grew MSD with Diabetes accelerating to HSD; transformational efforts and cost management drove outperformance on Q2 margins and EPS.

Material innovation: numerous major launches and approvals reinforce durability thesis

Expect product launches to ramp and contribute to H2 revenue growth and beyond:

- Cardiovascular: PFA systems, Aurora EV-ICD™, Evolut™ FX, Micra™ AV2 and VR2, and Symplicity Spyral™ RDN system
- Neuroscience: Inceptiv[™] SCS closed loop sensing and Percept[™] featuring BrainSense[™] technology
- Medical Surgical: Hugo™ Robotics-Assisted Surgery and GI Genius™ Al-driven endoscopy
- Diabetes: 780G™ system with Guardian™ 4 Sensor and Simplera™ stand-alone CGM

Raising FY24 revenue and EPS guidance Following H1 outperformance, raising FY24 organic revenue growth guidance to 4.75% [vs. prior +4.5%]. EPS now \$5.13 - \$5.19, 4 cent raise at the midpoint and includes incremental 3 cent H2 headwind for FX/tax

Comprehensive transformation and capital allocation

Executing comprehensive transformation; enhancing global operations, quality and supply chain; decisive 200 capital allocation geared toward next-gen technologies across Robotics, AI and Closed Loop systems

Confident in delivering durable revenue growth and shareholder value (\$)

Focused on translating durable revenue growth to leveraged earnings power with ongoing efforts to stabilize and then expand margins; committed to making our scale an advantage as the world's largest med tech company, all aimed at creating value for our shareholders.

We're delivering a track record of durable, mid-single digit revenue growth. The underlying fundamentals are strong, and our solid results were broad-based across our businesses and geographies.


We're bringing game changing innovation to market, with numerous recent regulatory approvals and major product launches, which give us confidence in our ability to continue delivering dependable growth"

GEOFF MARTHA, **CHAIRMAN & CEO**



Q2 FY24 Financial summary


Revenue¹ by segment



1) Data has been intentionally rounded to the nearest million and, therefore, may not sum.

Operating cash flows less property, plant, and equipment additions.

6 | Q2 FY24 Earnings Presentation | November 21, 2023




Q2 FY24 Regional organic revenue growth

Table ofExecutivePortfolioFinancialGuidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

▲ Mid-teens

5.0% WW growth benefited from MSD growth in Non-U.S. Developed markets; rebound in China helped offset Russia headwinds



V Low-20's

▲ Low-double digits

Medtronic

▲ High-teens


▲ Low-20's

▲ High-single digits

Key product approvals

Table ofExecutivePortfolioFinancialGuidance &SustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

Last 12 months: ~130 product approvals in key geographies¹



Note: Relative positioning is not intended to signify relative timing

1) Includes U.S., EU, Japan and China. Does not include all indication or partner approvals, though select additional approvals are displayed

8 | Q2 FY24 Earnings Presentation | November 21, 2023

Table of Executive Portfolio Financial Guidance &
Contents Summary Highlights Highlights AssumptionsSustainability Appendix

O2 FY24 Portfolio Highlights

Cardiovascular

5% growth driven by strong performance in Pacing, Diagnostics, Aortic, Cardiac Surgery and Coronary

Medtroni

Aurora EV-ICD

Cardiac Rhythm & Heart Failure (CRHF)

- Cardiac Pacing Therapies: HSD growth; LDD WW Micra™ growth driven by OUS adoption and U.S. launch of Micra AV2 and VR2; high-30s WW SelectSure™ 3830 lead growth, the only lead approved for conduction system pacing in the U.S.
- Defibrillation Solutions: LSD decline; Aurora EV-ICD[™] received FDA approval
- Diagnostics: HSD growth driven by LINQ II™; U.S. launch of AccuRhythm™ AI 2.0
- CAS: MSD growth driven by Arctic Front[™] cryoablation catheters; expanding Affera[™] mapping and focal ablation system LMR in Europe; received CE Mark for single-shot PulseSelect[™] PFA catheter (PMA submission under FDA review)

Structural Heart & Aortic (SHA)


- Structural Heart (TAVR): MSD growth on difficult US comp due to Evolut™ FX launch last vear and delayed purchases in EU ahead of Evolut™ FX launch
 - Evolut Low Risk Trial 4-year results show Evolut TAVR system demonstrated exceptional outcomes and sustained valve performance, proven by significantly better hemodynamics and continued separation in death and disabling stroke vs. SAVR
- Aortic: HSD growth on supply; LDD AAA growth aided by 10-year Endurant data release
- Cardiac Surgery: High-teens U.S. growth driven by strength in Cannula & Perfusion

Coronary and Peripheral Vascular (CPV)

- Coronary: Y/Y DES share gains driven by Onyx Frontier™ launch; HSD growth in Balloons and MSD growth in Guide Catheters
 - Received FDA approval for Symplicity Spyral[™] RDN system
- Peripheral Vascular Health: Mid-teens growth in DCBs driven by strength of IN.PACT™ 018 DCB; HSD growth in Vascular Embolization and MSD growth in Superficial Venous

Affera[™] and PulseSelect[™] are not commercially available in the U.S.





Neuroscience

4% growth benefitting from strength in Core Spine & Neurosurgery

Cranial & Spinal Technologies (CST)


- Core Spine: HSD growth, including MSD in the U.S., driven by AiBLE™ ecosystem pullthrough
- Neurosurgery: MSD growth overall, with double digit growth in StealthStation™ navigation and O-arm™ Surgical Imaging System in both the U.S. and OUS
 - Mazor[™] robotic system is the first and only solution to incorporate AI-based alignment planning with 3D hardware construct design tools and bone cutting technology
- Continued adoption of the AiBLE™ Spinal Ecosystem with its AI enabled surgical planning, implants, navigation, robotics, interoperative imaging, and surgical tools

Specialty Therapies (ST)

- Neurovascular: HSD growth (ex China) driven by low-20s growth in Flow Diversion and strong adoption of Shield Technology™
- Ear, Nose & Throat: Results impacted by TriVantage™ backorder, offset by mid-teens growth for Intersect™ and high-teens growth in Power disposables backorder recovery
- Pelvic Health: MSD ex-Enterra driven by low-20s growth in WE on cont'd InterStim[™] X adoption; Completed 6-month primary endpoint of TITAN 2 pivotal trial for less-invasive Tibial implant

Neuromodulation (NM)

- Spinal Cord Stimulation: LSD growth with HSD growth in U.S. driven by increasing trialing and implanting rates of our differentiated DTM[™] on Intellis[™] platform
 - Completed first European implants of Inceptiv[™], our next-generation SCS with closed-loop sensing
- Brain Modulation: LSD declines; MSD U.S. new implant growth, driven by Percept™ PC with BrainSense™ technology



Medical Surgical

6% growth driven by Advanced Surgical; GI Genius™ momentum continues

Surgical & Endoscopy (SE)

- Surgical: MSD Y/Y growth driven by supply expansion within Signia[™] powered stapler, LigaSure[™] vessel sealing, and V-Loc[™] barbed sutures
 - Advanced Stapling WW MSD growth driven Signia[™] stapling; WW Energy grew MSD sequentially
 - Hernia LDD growth on ProGrip[™] and Dextile[™] mesh sales; Wound Management MSD growth driven by V-loc[™] barbed suture and supply expansion
 - Hugo^{™1} RAS installed base increase, and the Expand URO U.S. pivotal trial continues; received FDA approval to move forward with an IDE for Hernia indication
- Endoscopy: LDD WW growth driven by procedure volumes strength and contributions from GI Genius™ Intelligent Endoscopy, Barrx™ Radiofrequency Ablation System, and Nexpowder™ Endoscopic Hemostasis System; Launched next-gen Endoflip™ 300 Impedance Planimetry System
 - Clinical benefits of Al-powered GI Genius[™] bolstered by 5th RCT: COLO-DETECT results presented at UEG Week, which validate improved adenoma detection rate

Patient Monitoring & Respiratory Interventions (PMRI)

- Patient Monitoring: LSD growth driven by high-20s growth in Nellcor™ pulse oximetry monitors, including RespArray[™] patient monitor; Respiratory Compromise grew LDD
- Respiratory Interventions: Flat growth supported by HSD Airways performance; Won • multiple key U.S. accounts with McGRATH™ MAC Video Laryngoscope




Signia™

Powered Stapler with Tri-Staple™

GI Genius™

Intelligent Endoscopy

Module



23%•••••• PMRI | \$501M +2.5% Y/Y Rep +1.8% Y/Y Org

Hugo™

RAS System¹

\$2,142M +7.0 Y/Y Rep

+5.6% Y/Y Org

SE | \$1,641M +8.5% Y/Y Rep

+6.8% Y/Y Org



Respiratory Interventions

Medtronic

Flat

Hugo[™] is not commercially available in the U.S. 1)

Diabetes

7% growth fueled by exceptional U.S. adoption of MiniMed[™] 780G system and continued double digit international growth

United States

Low 30s Q/Q revenue growth in 1st full quarter of MiniMed™ 780G system launch; new patient adds surpassed 3-year highs

- Leading indicators point to strong recovery; outlook calls for return to Y/Y growth in H2 FY24
- Installed base grew in Q2 FY24; new patient growth >60% Y/Y benefitting from increasing MDI share gain
- >20% Q/Q growth in unique 780G prescribers; driving competitive conversions with \$499 in-warranty upgrade program
- Experiencing lift for Guardian™ 4 sensor CGM attachment rates; adds confidence to recurring revenue stream

International

Consistent mid-teens growth driven by MiniMed™ 780G system expansion and CGM growth

- WE: Medtronic remains the market leader with mid-teens growth; HCP's first choice in AID therapy²
- Other International: Launched MinMed™ 780G system in Korea with Japan anticipated Q3 FY24
- NICE guidelines established AID as standard of care in UK; totality of evidence continues to drive diabetes care towards system-first approach, reinforcing CGM alone is not enough to drive outcomes


Pipeline

Advancing next-gen pipeline to offer the largest portfolio of diabetes solutions

- MiniMed 780G[™] system with Simplera[™]: Filed for CE Mark; Fully enrolled U.S. pivotal (ages 7-80) with final study completion expected in FY24Q4; followed by 780G+Simplera FDA submission expected in H1 CY24
- Secured CE Mark for next-gen CGM, Simplera, access 30+ EMEA countries; first commercial patients started in October with expanded rollout in 2H; 50% smaller fully disposable with 2-step insertion and no fingersticks
- On track to bring a differentiated patch system to U.S. with our next-gen sensor and Meal Detection[™] Technology, as well as next generation durable pump system

1) 79% Time In Range using recommended settings as shown in real-world evidence for MM780G system (n=5,762)

- 2) Seagrove Partners 2023 survey (N=330) of European HCPs perspective on AID systems
- 13 | Q2 FY24 Earnings Presentation | November 21, 2023





MiniMed™ 780G system Global Real-world Data Achieves ~80% TIR¹



Simplera™ CE Mark Approved; Currently Under FDA Review

Table ofExecutivePortfolioFinancialGuidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

O2 FY24 Financial Highlights



Q2 FY24 Income statement

Table of Executive Portfolio Financial Guidance & Sustainability Appendix Contents Summary Highlights Highlights Assumptions

G	A,	4	D1
---	----	---	----

(\$ in millions)	Q2 FY23	Q2 FY24	Y/Y
Revenue	\$7,585	\$7,984	5.3%
Gross Margin	66.6%	65.4%	-120 bps
SG&A % of Sales	34.5%	33.6%	-90 bps
R&D % of Sales	8.9%	8.7%	-20 bps
Operating Margin	18.5%	16.8%	-170 bps
Net Income	\$427	\$909	112.9%
Diluted EPS	\$0.32	\$0.68	112.5%

Full GAAP to non-GAAP reconciliation in Appendix

Non-GAAP¹

(\$ in millions)	Q2 FY23	Q2 FY24	Y/Y
Revenue	\$7,585	\$7,984	5.3%
Gross Margin	67.6%	65.9%	-170 bps
SG&A % of Sales	33.8%	32.9%	-90 bps
R&D % of Sales	8.7%	8.6%	-10 bps
Operating Margin	26.6%	25.2%	-140 bps
Net Income	\$1,725	\$1,667	-3.4%
Diluted EPS	\$1.30	\$1.25	-3.8%

1) The data in this table has been intentionally rounded and, therefore, may not sum; Dollars in millions except for EPS.

15 | Q2 FY24 Earnings Presentation | November 21, 2023

Mectronic

Exercising decisive capital allocation

Table of Executive Portfolio Financial Guidance & Sustainability Appendix Contents Summary Highlights Highlights Assumptions

Prioritizing innovation-driven growth investments while delivering consistent dividends to shareholders




Table ofExecutivePortfolioFinancialGuidance &ContentsSummaryHighlightsHighlightsAssumptions

Guidance & Assumptions

Guidance and assumptions

Table ofExecutivePortfolioFinancialGuidance &
Guidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

FY24 REVENUE	FY23 k	base ¹	Organic revenue growth guidance	FX ²	Inorganic	Other ³	Implied reported revenue range	
Q4 Earnings Call May 25, 2023	FY23 Reported	\$31,227M	4.0% to 4.5%	+\$110M to +\$210M	\$0	~\$50M	~\$32.0B to \$32.3B	
	Less IP Agreement	(\$265M)						
Q1 Earnings Call August 22, 2023	Less Other ²	(\$300M)	4.5%	(\$25M) to +\$75M	\$0	~\$50M	~\$32.1B to \$32.2B	
Q2 Earnings Call November 21, 2023	FY23 base	\$30,662M	4.75%	(\$200M) to (\$100M)	\$0	~\$65M	~\$32.0B to \$32.1B	

FY24 EPS	FY23 base	Implied constant currency growth	FX ²	FY24 EPS guidance
Q4 Earnings Call _{May} 25, 2023		+1% to +3%	~(6%)	\$5.00 to \$5.10
Q1 Earnings Call _{August} 22, 2023	\$5.29	+2% to +3%	~(6%)	\$5.08 to \$5.16
Q2 Earnings Call November 21, 2023		+3% to +4%	~(6%)	\$5.13 to \$5.19

Note: EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year

1) FY23 reported revenue of \$31,227 less IP Agreement of \$265M and less Other of \$300M

2) While FX rates are fluid, assumptions above are based on rates as of November 2023

3) Other includes Mozarc Medical and Cardinal Health Manufacturing Agreements

18 | Q2 FY24 Earnings Presentation | November 21, 2023

Table ofExecutivePortfolioFinancialGuidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

Sustainability

Sustainability

Leading in engagement, citizenship and innovation

Table of
Contents SummaryPortfolio
HighlightsFinancial
HighlightsGuidance &
SummarySustainabilityAppendix

DiversityInc TOP 2023 DiversityInc #2 in Diversity Top 50, #2 for Mentorship, #7 for Supplier Diversity, #5 for ESG, #1 for Top company for executive women, #1 for Latino executives, #4 for Asian American executives	2022 Great Place To Work ® And Fortune Magazine #12 Worlds Best Workplaces™	Great Place to Work ® certified awarded to Medtronic in Australia, Greater China, Spain, and 20 other countries	BEEST PLACES TO WORK 2022 for LGBTQ+ Equality TOW CORPORATE EQUALITY THOEX Human Rights Campaign 100% Corporate Equality Index Human Rights Campaign - Best Places to Work for LGBTQ+ in South America - Medtronic Chile	U.S. Chamber of Commerce Foundation U.S. Chamber of Commerce Foundation Best Corporate Citizens Awards Named Best Corporate Steward - Large Business
Top Employers Institute certified Awarded to Medtronic in the U.K., Egypt, South Africa, and 6 other countries	Ethisphere One of the 2023 Worlds Most Ethical Companies®	Mectronic2023 Bist Placeto Work forDisability:IN and the AmericanAssociation of People withDisabilities Disability Equality Index®Best Places to Work™ – 100% Score6th consecutive year with top score	2023 Hispanic Association on Corporate Responsibility 5-star awards across all 4 pillars – Employment, Philanthropy, Procurement, & Governance – 2 nd consecutive year	Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA Dow Jones Sustainability Index DJSI World Index for 2 consecutive years DJSI North American Index for 15 consecutive years
Named one of America's 2022 Best Employers for Veterans by Forbes Forbes America's Best Employers for Veterans 2022 20 Q2 FY24 Earnings Presentation November 21, 20	Glassdoor Glassdoor Best Places to Work 2022	Just Capital Named one of America's Most JUST Companies by JUST Capital	Best Workplaces Frewore Breat	IR Magazine 2023 Best IR Website; Runner-up for Best IR in Healthcare
		more, visit our <u>awards</u> pa	age	meanorme

Near and long-term sustainability objectives

Table ofExecutivePortfolioFinancialGuidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix

Robust governance structures and processes underpin our sustainability strategy

		Sustainability targets and progress	Baseline	End date	FY23 status
		Reduce greenhouse gas emissions intensity by 50%	FY20	FY25	35%
		Reduce energy intensity by 20%	FY20	FY25	6%
		Source 50% of energy from renewable and alternative sources	FY20	FY25	31% ¹
	Climate stewardship	Reduce water usage intensity by 15%	FY20	FY25	9 %
-	stewardship	Reduce waste intensity by 15%	FY20	FY25	17%
		Become carbon neutral in our operations (scope 1 and 2)	N/A	FY30	On track
		Reach net-zero emissions	N/A	FY45	On track
		Reduce packaging waste by 25% for four ² targeted high-volume product families ³	FY21	FY25	7%
	Product stewardship	Minimize impact of instructions for use (IFU) through a 35% paper reduction	FY21	FY27	1%
		Publish partial life cycle assessments (LCA) for 100% of products and full LCAs for 50% of products	N/A	FY30	New in FY23
		Convert 50% of eligible product codes to electronic IFUs within applicable regions	N/A	FY30	New in FY23
s		Integrate circularity and eco-design criteria into the New Product Development process	N/A	FY30	New in FY23
		Achieve one of the following for 95% of eligible plastic packaging: is industrially recyclable, contains postindustrial recycled content, demonstrates optimized design	N/A	FY30	New in FY23
		Reduce packaging for 20 additional high-volume products for a total of 50% reduction	N/A	FY30	New in FY23
	Access and	Flow 20% of revenue from products released in the prior 36 months (vitality index)	N/A	FY25	16%
	Innovation	Serve 79 million patients annually through strategies that increase healthcare access ⁴	N/A	FY25	74 million +
Pr	roduct quality	Reduce aggregate product complaint rate by 10% for identified product families ⁵	FY20	FY25	39 %
		Reach 45% representation of women in manager-and-above roles globally	N/A	FY26	43%
	ID&E	Reach 30% representation of ethnically diverse groups in manager-and-above roles in the U.S.	N/A	FY26	28%
		Increase spend with U.S. diverse-owned suppliers by 5% Y/Y through FY26	FY22	FY23	37%

1. Annual progress is cumulative and represented as the growth in sourcing over the FY20 baseline year. Value includes purchases renewable electricity credits.

2. Four product families include: Tri-staple, Polysorb, Absorbatack, Spinal Implants


3. High-volume product families identified based on weight, material selection, and sourcing

4. Target was adjusted in FY23 after announcement of plans to divest the PMRI businesses

5. For more information see page 17 of the FY23 Sustainability Report found on the Medtronic Investor Relations website

21 Q2 FY24 Earnings Presentation | November 21, 2023

Table ofExecutivePortfolioFinancialGuidance &
SustainabilitySustainabilityAppendixContentsSummaryHighlightsHighlightsAssumptionsSustainabilityAppendix



Appendix

Q2 FY24 Revenue by portfolio and geography

Table ofExecutivePortfolioFinancialGuidance &ContentsSummaryHighlightsHighlightsAssumptions

		Worldwide			U.S.		Ν	Non-U.S. Developed			Emerging Markets	
	Revenue (\$M) ¹	As reported Y/Y%	Organic Y/Y%									
Cardiovascular	2,923	5.9	4.8	1,427	1.2%	1.2%	912	13.7%	8.4%	584	7.0%	9.2%
Cardiac Rhythm & Heart Failure	1,492	5.3%	4.0%									
Structural Heart & Aortic	819	8.2%	6.7%									
Coronary & Peripheral Vascular	613	5.0%	4.6%									
Neuroscience	2,288	4.7%	4.2%	1,560	3.2%	3.2%	399	4.5%	0.8%	329	12.7%	14.0%
Cranial & Spinal Technologies	1,157	7.0%	6.7%									
Specialty Therapies	705	2.8%	2.6%									
Neuromodulation	426	1.7%	0.5%									
Medical Surgical	2,142	7.0%	5.6%	963	7.6%	7.6%	740	8.0%	4.1%	438	4.0%	3.8%
Surgical & Endoscopy	1,641	8.5%	6.8%									
Patient Monitoring & Respiratory Interventions	501	2.5%	1.8%									
Diabetes	610	9.7%	6.7%	217	-4.8%	-4.8%	310	22.0%	15.0%	84	13.5%	14.9%
Other	22	-73.2%	-	8	-65.2%	-	7	- 78.8 %	-	7	-72.0%	-
Total Medtronic	7,984	5.3%	5.0%	4,175	2.6%	3.0%	2,368	9.8 %	6.4%	1,441	6.0%	8.8%

1) Data has been intentionally rounded to the nearest million and, therefore, may not sum

23 Q2 FY24 Earnings Presentation | November 21, 2023

Q2 FY24 GAAP to non-GAAP reconciliations

Table ofExecutivePortfolioFinancialGuidance &ContentsSummaryHighlightsHighlightsAssumptions

	Q2 FY24 GAAP	Amortization	Restructuring	Certain Litigation	Acquisition and Divestiture- Related Items	(Gain) / Loss on Minority Investment	Medical Device Regulations	Certain Tax Adjustments	Q2 FY24 Non-GAAP	Q2 FY23 Non-GAAP	Y/Y Growth / Change
Net Sales	7,984	-	-	-	-	-	-	-	7,984	7,585	5.3%
Cost of Products Sold	2,761	-	(15)	-	(6)	-	(21)	-	2,720	2,454	10.8%
Gross Margin	65.4%	-	0.2%	-	0.1%	-	0.3%	-	65.9%	67.6%	-170 bps
SG&A	2,686	-	(36)	-	(26)	-	-	-	2,623	2,563	2.3%
% of Sales	33.6%	-	(0.5%)	-	(0.3%)	-	-	-	32.9%	33.8%	-90 bps
R&D	698	-	-	-	-	-	(9)	-	688	659	4.4%
% of Sales	8.7%	-	-	-	-	-	(0.1)%	-	8.6%	8.7%	-10 bps
Other Operating Expense (Income), Net	(31)	-	-	-	(26)	-	-	-	(57)	(112)	(49.1%)
% of Sales	(0.4%)	-	-	-	(0.3)%	-	-	-	(0.7%)	(1.5%)	-80 bps
Amortization of Intangible Assets	425	(425)	-	-	-	-	-	-	-	-	-
Restructuring Charges, Net	40	-	(40)	-	-	-	-	-	-	-	-
Certain Litigation Charges	65	-	-	(65)	-	-	-	-	-	-	-
Operating Profit	1,340	425	91	65	58	-	30	-	2,009	2,020	(0.5%)
Operating Margin	16.8%	5.3%	1.1%	0.8%	0.7%	-	0.4%	-	25.2%	26.6%	-140 bps
Other Non-Operating Income, Net	(154)	-	-	-	-	(25)	-	-	(179)	(98)	82.7%
Net Income Attributable to MDT (\$M)	909	360	76	50	51	21	24	176	1,667	1,725	(3.4%)
Diluted EPS (\$) ⁽¹⁾	0.68	0.27	0.06	0.04	0.04	0.02	0.02	0.13	1.25	1.30	(3.8%)


1) Data has been intentionally rounded to the nearest million or \$0.01 for EPS figures and, therefore, may not sum

24 Q2 FY24 Earnings Presentation | November 21, 2023

Mectronic

FY24 Medtronic business structure

Table of Executive Portfolio Financial Guidance & Sustainability Appendix Contents Summary Highlights Highlights Assumptions



* Medtronic Care Management Services reported as part of Cardiac Rhythm Management in FY23 moved to Patient Monitoring for FY24

** Previously included within Medical Surgical Portfolio

Abbreviations & acronyms

Table of
Contents SummaryPortfolio
HighlightsFinancial
HighlightsGuidance &
SummarySustainabilityAppendix

	Growth		Business specific		Business specific		Other		
•	Revenue Decreased Y/Y Organic	AAA	Abdominal Aortic Aneurysm	ICD	Implantable Cardioverter Defibrillator	ADA	American Diabetes Association		
—	Revenue flat Y/Y Organic	AID	Automated Insulin Delivery	MDI	Multiple Daily Injections	Ex-Vent	Excluding Ventilator		
	Revenue Increased Y/Y Organic	CAS	Cardiac Ablation Solutions	PFA	Pulse Field Ablation	НСР	Health Care Provider		
WAMGR	Weighted Average Market Growth Rate	CGM	Continuous Glucose Monitoring	RAS	Robot-Assisted Surgery	IDE	Investigational Device Exemption		
		CRM	CRM Cardiac Rhythm Management		Renal Denervation	ID&E	Inclusion, Diversity and Equity		
		CRT-D	Cardiac Resynchronization Therapy - Defibrillator	SAVR	Surgical Aortic Valve Replacement	NICE	National Institute for Health and Care Excellence		
		DBS	Deep Brain Stimulation	SCS	Spinal Cord Stimulation	OU	Operating Unit		
		DCB	Drug Coated Balloon	SVD	Structural Valve Deterioration	RCT	Randomized Controlled Trial		
		DES	Drug Eluting Stent	ΤΑΑ	Thoracic Aortic Aneurysm	UEG	United European Gastroenterology		
		DTM	Differential Target Multiplexed Waveform	TAVR	Transcatheter Aortic Valve Replacement	VBP	Volume-Based Procurement		
		ENT	ENT Ear, Nose, & Throat		Time In Range	WE	Western Europe		
		EV-ICD Extravascular Implantable Cardioverter Defibrillator		URO	Urology	WW	World Wide		
		GI	Gastrointestinal						



Investor Relations contact information



Ryan Weispfenning Vice President Head of Investor Relations



Brad Welnick Vice President Investor Relations



Gregory Hertz Senior Director Investor Relations

investor.relations@medtronic.com



